-
EP4013755
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4013755
| EP4013755 - PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS [Right-click to bookmark this link] | Status | Grant of patent is intended Status updated on 29.07.2024 Database last updated on 19.10.2024 | |
| Former | Request for examination was made Status updated on 20.07.2024 | ||
| Former | Grant of patent is intended Status updated on 17.03.2024 | ||
| Former | Request for examination was made Status updated on 20.05.2022 | ||
| Former | The international publication has been made Status updated on 19.02.2021 | ||
| Former | unknown Status updated on 28.08.2020 | Most recent event Tooltip | 27.08.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Novartis AG Lichtstrasse 35 4056 Basel / CH | [2022/25] | Inventor(s) | 01 /
DENG, Haibing Room 502, Building 19 Lane 1288 Pujian Road Pudong New District Shanghai 201204 / CN | 02 /
LIU, Jinbiao China Novartis Institutes for BioMedical Research Co., Ltd. 4218 Jinke Road Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203 / CN | 03 /
OYANG, Counde 1420 Bellingham Way Sunnyvale, California 94087 / US | 04 /
WANG, Ce China Novartis Institutes for BioMedical Research Co., Ltd. 4218 Jinke Road Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203 / CN | 05 /
XIAO, Qitao China Novartis Institutes for BioMedical Research Co., Ltd. 4218 Jinke Road Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203 / CN | 06 /
XUN, Guoliang Room 303, 53-4 Building Chengshi Huayuan South Xianfu Road Taicang City, Jiangsu 215400 / CN | 07 /
ZENG, Haiqiang China Novartis Institutes for BioMedical Research Co., Ltd. 4218 Jinke Road Zhangjiang Hi-Tech Park, Pudong New Area Shanghai 201203 / CN | [2022/25] | Representative(s) | Graham Watt & Co LLP St. Botolph's House 7-9 St. Botolph's Road Sevenoaks TN13 3AJ / GB | [2022/25] | Application number, filing date | 20757967.3 | 12.08.2020 | [2022/25] | WO2020IB57602 | Priority number, date | WO2019CN100542 | 14.08.2019 Original published format: PCT/CN2019/100542 | [2022/25] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021028854 | Date: | 18.02.2021 | Language: | EN | [2021/07] | Type: | A1 Application with search report | No.: | EP4013755 | Date: | 22.06.2022 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.02.2021 takes the place of the publication of the European patent application. | [2022/25] | Search report(s) | International search report - published on: | EP | 18.02.2021 | Classification | IPC: | C07D473/34, C07D471/04, C07D519/00, A61P35/00, A61K31/52 | [2022/25] | CPC: |
C07D473/34 (EP,CN,IL,KR,US);
C07D471/04 (EP,CN,IL,KR);
A61K31/52 (KR);
A61P35/00 (EP,CN,IL,KR);
A61P35/02 (CN);
C07D519/00 (EP,IL)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/25] | Title | German: | PIPERIDINYL-METHYL-PURINAMINE ALS NSD2-INHIBITOREN UND ANTIKREBSMITTEL | [2022/25] | English: | PIPERIDINYL-METHYL-PURINEAMINES AS NSD2 INHIBITORS AND ANTI-CANCER AGENTS | [2022/25] | French: | PIPÉRIDINYL-MÉTHYL-PURINEAMINES EN TANT QU'INHIBITEURS DE NSD2 ET AGENTS ANTICANCÉREUX | [2022/25] | Entry into regional phase | 12.03.2022 | National basic fee paid | 12.03.2022 | Designation fee(s) paid | 12.03.2022 | Examination fee paid | Examination procedure | 12.03.2022 | Examination requested [2022/25] | 12.03.2022 | Date on which the examining division has become responsible | 22.09.2022 | Amendment by applicant (claims and/or description) | 18.03.2024 | Communication of intention to grant the patent | 18.07.2024 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 30.07.2024 | Communication of intention to grant the patent | Fees paid | Renewal fee | 29.08.2022 | Renewal fee patent year 03 | 28.08.2023 | Renewal fee patent year 04 | 27.08.2024 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]CN108853110 (UNIV JIANGSU TECHNOLOGY); | [A]CN109223794 (UNIV JIANGSU TECHNOLOGY); |